Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of intravitreal lampalizumab in geographic atrophy
2016-000423-13Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2016
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lampalizumab in age-related macular degeneration (AMD) and geographic atrophy (GA), sponsored by Roche. Primary endpoint: Percentage of participants with ocular adverse events by severity. Started Aug 2016; status: completed.
02
Drugs
lampalizumab
03
Conditions
age-related macular degeneration (AMD)geographic atrophy (GA)
Beyond the preview
Go deeper on 2016-000423-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000423-13.